Office of the Commissioner
Effective March 31, 2019, FDA began operational implementation of an agency reorganization. FDA’s reorganization reflects the agency’s commitment to modernizing its structure to advance its mission to protect and promote public health, and to meet the challenges of rapid innovation across the industries regulated by FDA. The FDA’s reorganization has realigned several entities across the agency to promote strategic priorities, and will elevate the role of the centers, offices and field forces.
This organization chart reflects the new structure.